T1	CHEM 57 66	nivolumab
#1	AnnotatorNotes T1	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T2	DISO 101 103	LF
#2	AnnotatorNotes T2	C0024301; Lymphoma, Follicular; Neoplastic Process
T3	DISO 82 99	linfoma folicular
#3	AnnotatorNotes T3	C0024301; Lymphoma, Follicular; Neoplastic Process
T4	PROC 153 191	Estudio fase 2 de brazo único, abierto
T5	CHEM 196 205	Nivolumab
#4	AnnotatorNotes T5	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T6	DISO 253 255	LF
#5	AnnotatorNotes T6	C0024301; Lymphoma, Follicular; Neoplastic Process
T7	DISO 234 251	linfoma folicular
#6	AnnotatorNotes T7	C0024301; Lymphoma, Follicular; Neoplastic Process
T8	PROC 284 293	Protocolo
#7	AnnotatorNotes T8	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T9	DISO 360 379	Linfoma non-Hodgkin
T10	DISO 406 408	LF
#8	AnnotatorNotes T10	C0024301; Lymphoma, Follicular; Neoplastic Process
T11	PROC 593 604	tratamiento
#9	AnnotatorNotes T11	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T12	PROC 642 653	tratamiento
#10	AnnotatorNotes T12	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T13	CHEM 688 704	anticuerpo CD 20
T14	CHEM 709 728	agentes alquilantes
#11	AnnotatorNotes T14	C0002073; Alkylating Agents; Hazardous or Poisonous Substance · Pharmacologic Substance
T15	PROC 995 1019	TPH alogénico o autólogo
T16	DISO 521 538	Linfoma folicular
#12	AnnotatorNotes T16	C0024301; Lymphoma, Follicular; Neoplastic Process
T17	DISO 836 843	Linfoma
#13	AnnotatorNotes T17	C0024299; Lymphoma; Neoplastic Process
T18	ANAT 857 881	sistema nervioso central
#14	AnnotatorNotes T18	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T19	PROC 1028 1040	TPH autologo
T20	DISO 896 928	enfermedad pulmonar intersticial
#15	AnnotatorNotes T20	C0206062; Lung Diseases, Interstitial; Disease or Syndrome
T21	DISO 941 962	enfermedad autoinmune
#16	AnnotatorNotes T21	C0004364; Autoimmune Diseases; Disease or Syndrome
T22	CHEM 1091 1102	medicamento
#17	AnnotatorNotes T22	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T23	CHEM 207 217	BMS-936558
#18	AnnotatorNotes T23	C4552119; BMS-936558; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T24	ANAT 907 915	pulmonar
#19	AnnotatorNotes T24	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T25	ANAT 916 928	intersticial
#20	AnnotatorNotes T25	C0596790; interstitial; Body Location or Region | C2328510; Interstitium; Body Part, Organ, or Organ Component
T26	Date 13 17	2013
T27	LIVB 70 77	sujetos
#21	AnnotatorNotes T27	C0681850; Study Subject; Group
T28	LIVB 222 229	sujetos
#22	AnnotatorNotes T28	C0681850; Study Subject; Group
T31	LIVB 489 496	mujeres
#23	AnnotatorNotes T31	C0043210; Woman; Population Group
T32	Age 501 508	18 años
T34	LIVB 929 936	Sujetos
#24	AnnotatorNotes T34	C0681850; Study Subject; Group
T35	Spec_cue 982 992	sospechada
T36	Duration 1048 1060	≤ 12 semanas
T37	CONC 1073 1086	primera dosis
T29	LIVB 479 486	Varones
#25	AnnotatorNotes T29	C0025266; Male population group; Population Group
T30	PROC 732 748	Estado funcional
#26	AnnotatorNotes T30	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T33	PROC 750 752	EF
#27	AnnotatorNotes T33	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T38	DISO 108 116	recidiva
#28	AnnotatorNotes T38	C2825055; Recurrence (disease attribute); Pathologic Function
T39	DISO 260 268	recidiva
#29	AnnotatorNotes T39	C2825055; Recurrence (disease attribute); Pathologic Function
T40	DISO 542 549	recaida
#30	AnnotatorNotes T40	C0699753; Cancer Relapse; Neoplastic Process
T41	PROC 442 459	anatomopatológica
#31	AnnotatorNotes T41	C0200712; Anatomic pathology procedure; Laboratory Procedure
T42	CONC 758 792	Eastern Cooperative Oncology Group
T43	CONC 794 798	ECOG
T44	Result_or_Value 803 808	0 ó 1
T45	Quantifier_or_Qualifier 119 130	refractario
T46	Quantifier_or_Qualifier 271 282	refractario
T47	Quantifier_or_Qualifier 412 427	grado 1, 2 o 3a
T48	Quantifier_or_Qualifier 552 563	refractario
T49	Quantifier_or_Qualifier 575 589	2 o más lineas
T50	Quantifier_or_Qualifier 676 687	al menos un
A1	Assertion T21 Speculated
A2	Status T20 History_of
A3	Status T15 History_of
A4	Status T19 History_of
A5	Status T11 History_of
A6	Status T12 History_of
A7	Status T17 History_of
A8	Status T21 History_of
R1	Speculation Arg1:T35 Arg2:T21
R2	Location_of Arg1:T18 Arg2:T17
R3	Location_of Arg1:T24 Arg2:T20
R4	Location_of Arg1:T25 Arg2:T20
R5	Experiences Arg1:T34 Arg2:T21
R6	Overlap Arg1:T19 Arg2:T36
R7	Has_Dose_or_Strength Arg1:T22 Arg2:T37
R9	Has_Result_or_Value Arg1:T43 Arg2:T44
R10	Has_Result_or_Value Arg1:T42 Arg2:T44
R11	Used_for Arg1:T42 Arg2:T33
R12	Used_for Arg1:T42 Arg2:T30
R13	Used_for Arg1:T43 Arg2:T33
R14	Used_for Arg1:T43 Arg2:T30
R15	Experiences Arg1:T27 Arg2:T3
R16	Experiences Arg1:T27 Arg2:T2
R17	Experiences Arg1:T27 Arg2:T38
R18	Experiences Arg1:T28 Arg2:T7
R19	Experiences Arg1:T28 Arg2:T6
R21	Experiences Arg1:T28 Arg2:T39
R23	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T47
R24	Has_Age Arg1:T31 Arg2:T32
R25	Has_Age Arg1:T29 Arg2:T32
R26	Experiences Arg1:T31 Arg2:T16
R27	Experiences Arg1:T29 Arg2:T16
R28	Experiences Arg1:T29 Arg2:T40
R30	Experiences Arg1:T31 Arg2:T40
R32	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T49
R33	After Arg1:T40 Arg2:T11
R34	Used_for Arg1:T14 Arg2:T12
R35	Used_for Arg1:T13 Arg2:T12
R36	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T50
R37	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T50
R38	After Arg1:T48 Arg2:T11
R39	Experiences Arg1:T28 Arg2:T23	
R40	Experiences Arg1:T28 Arg2:T5	
R41	Experiences Arg1:T27 Arg2:T1	
T51	Neg_cue 428 431	sin
T52	Observation 432 477	evidencia anatomopatológica de transformación
A9	Assertion T52 Negated
R42	Negation Arg1:T51 Arg2:T52	
T53	Quantifier_or_Qualifier 630 638	2 lineas
R43	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T53	
R44	Experiences Arg1:T29 Arg2:T11	
R45	Experiences Arg1:T29 Arg2:T12	
R46	Experiences Arg1:T31 Arg2:T11	
R47	Experiences Arg1:T31 Arg2:T12	
#32	AnnotatorNotes T45	C0205269; Unresponsive to Treatment; Functional Concept
R20	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T45	
R48	Has_Quantifier_or_Qualifier Arg1:T2 Arg2:T45	
#33	AnnotatorNotes T46	C0205269; Unresponsive to Treatment; Functional Concept
R22	Has_Quantifier_or_Qualifier Arg1:T6 Arg2:T46	
R49	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T46	
#34	AnnotatorNotes T48	C0205269; Unresponsive to Treatment; Functional Concept
R29	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T48	
R31	Used_for Arg1:T14 Arg2:T11	
R50	Used_for Arg1:T13 Arg2:T11	
#35	AnnotatorNotes T42	C1520224; ECOG performance status; Intellectual Product
#36	AnnotatorNotes T43	C1520224; ECOG performance status; Intellectual Product
T54	Quantifier_or_Qualifier 963 969	activa
R51	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T54	
#37	AnnotatorNotes T9	C0024305; Lymphoma, Non-Hodgkin; Neoplastic Process
#38	AnnotatorNotes T54	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R52	Before Arg1:T2 Arg2:T38	
R53	Before Arg1:T3 Arg2:T38	
R54	Before Arg1:T7 Arg2:T39	
R55	Before Arg1:T6 Arg2:T39	
R56	Before Arg1:T16 Arg2:T40	
R58	After Arg1:T40 Arg2:T12	
R57	After Arg1:T48 Arg2:T12	
#39	AnnotatorNotes T37	C5236155; Date of First Dose; Temporal Concept
#40	AnnotatorNotes R7	(?)
R59	Before Arg1:T19 Arg2:T37	
#41	AnnotatorNotes T15	C4255274; allogeneic hematopoietic stem cell transplant; Therapeutic or Preventive Procedure | C2193200; Autologous haematopoietic stem cell transplant; Therapeutic or Preventive Procedure
#42	AnnotatorNotes T19	C2193200; Autologous haematopoietic stem cell transplant; Therapeutic or Preventive Procedure
A10	Experiencer T27 Patient
A11	Experiencer T28 Patient
A12	Experiencer T29 Patient
A13	Experiencer T31 Patient
A14	Experiencer T34 Patient
